The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial

By sjmartinez • April 27, 2025

Golub LS, Manubolu VS, Aldana-Bitar J, Dahal S, Verghese D, Alalawi L, Krishnan S, Kianoush S, Benzing T, Ichikawa K, Kinninger A, Fazlalizadeh H, Pourafkari L, Ahmad K, Susarla S, Mangaoang C, Ghanem AK, Javier DA, Hamal S, Roy SK, Budoff MJ. The impact of semaglutide on liver fat assessed by serial cardiac CT scans in patients with type 2 diabetes: Results from STOP trial. Nutr Metab Cardiovasc Dis. 2025 Apr 5:104036. doi: 10.1016/j.numecd.2025.104036. Epub ahead of print. PMID: 40287313.

Tags: ASCVD, atherosclerotic cardiovascular disease, CAC, Cardiology/Epi, cardiovascular disease, Computed Tomography Angiography, coronary artery calcium, CTA, CVD, General Internal Medicine, GLP1 receptor agonists, Harbor UCLA, HCC, Hepatocellular carcinoma, MASH, MASLD, Metabolic dysfunction-associated Steatohepatitis, Metabolic dysfunction-associated steatotic liver disease, Publications, randomized trial, Resident, semaglutide

Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn’t

Talishinsky A, Ajijola OA, Salhi RA. Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn't. J Am Heart Assoc. 2025[...]

Early Structural Deterioration of a Self-Expanding Transcatheter Aortic Valve Prosthesis Presenting With Severe Aortic Insufficiency: A Case Report

Dave PR, Hacobian M. Early Structural Deterioration of a Self-Expanding Transcatheter Aortic Valve Prosthesis Presenting With Severe Aortic Insufficiency: A Case Report. Cureus. 2025 Sep[...]

Comorbidity patterns and mortality in HFpEF: A retrospective longitudinal cohort study

Yousufuddin M, Ma Z, Barkoudah E, Tahir MW, Yazdanyar A, Chikkanna R, Benkhadra K, Bhagra S, Fonarow GC, Yamani MH. Comorbidity patterns and mortality in[...]